• Mon news: AZ obesity pill. 50% of drug shortages last at least 2 years. Pharmas and IRA lawsuit appeals. Novo-Ascendis biobucks deal. Wegovy reduces all-cause hospital admissions. See more on our front page

Novo falters while Lilly has a kick-a$$ new diabetes drug coming

Quote

anonymous

Guest
How ironic? While novo can’t decide whether it wants health systems or not, whether pissing customers off every year with foot print changes is worth it not. Lilly did the humane way of cutting ppl by offering early retirement and options to have the dignity that employees deserve. Here Novo is constantly breeding chaos so ppl leave by natural attrition and Novo doesn’t have to pay. So very sad to see this once wonderful company in shambles.
 


















anonymous said:
40% nausea and 2x+more vomiting in the phase 2 trial.
Click to expand...

And double the weight loss of Sema.

I would try it with every patient, titration slowly and watch the magic.

I will use sema until then, but as an actual prescriber who is about to be laid off I will always use what’s best for the patient and it looks like Novo has a few goodbye years, burn not for long!!!
 




anonymous said:
And double the weight loss of Sema.

I would try it with every patient, titration slowly and watch the magic.

I will use sema until then, but as an actual prescriber who is about to be laid off I will always use what’s best for the patient and it looks like Novo has a few goodbye years, burn not for long!!!
Click to expand...

If they can’t get nausea down in the trial do you really think every day patients are going to be able to tolerate this in a reasonable fashion?
 
























anonymous said:
sema is a pill. Both will have their place
Click to expand...
Yeah, oral sema is a pill but it'll still be a GLP-1 which is priced much higher than the best pills in the market place. Very challenging to see how oral sema can be a success unless the price is at the level of the SGLT2s - but that will hurt injectable sema big time as we'll be eating our own tail for dinner. Brace for impact!
 




anonymous said:
Yeah, oral sema is a pill but it'll still be a GLP-1 which is priced much higher than the best pills in the market place. Very challenging to see how oral sema can be a success unless the price is at the level of the SGLT2s - but that will hurt injectable sema big time as we'll be eating our own tail for dinner. Brace for impact!
Click to expand...

All it has to do is be priced less or at parity with other glp1 to have similar access ya rube
 




anonymous said:
Yeah, oral sema is a pill but it'll still be a GLP-1 which is priced much higher than the best pills in the market place. Very challenging to see how oral sema can be a success unless the price is at the level of the SGLT2s - but that will hurt injectable sema big time as we'll be eating our own tail for dinner. Brace for impact!
Click to expand...

You obviously don't work for Novo, or if you do you have no inside knowledge of how oral sema would be launched if approved.

#sad #fakenews
 




anonymous said:
You obviously don't work for Novo, or if you do you have no inside knowledge of how oral sema would be launched if approved.

#sad #fakenews
Click to expand...
OK, Novo's very own Donald T, please share with us what the fake news is about. How about starting with the facts?
1. Empaglifozin (Jardiance) is the only treatment for T2D with an FDA approved label "to reduce the risk of cardiovascular death in adults with type 2 diabetes and established cardiovascular disease." Not even Ozempic could get that kind of label approved in the US!
2. Oral sema only narrowly beat Jardiance on HbA1c in the PIONEER 2 trial while there was no statistically significant difference in weight loss.
3. 11% of people treated with oral sema discontinued treatment due to nausea whereas only 4% dropped out in the Jardiance arm.
4. Ozempic and Trulicity are right now priced at least 35-40% higher than Jardiance.

Those were the facts. What is it we don't get here? That Novo is being carried away by the ability to put a protein into a tablet? Big deal. The patients - and importantly the payers - couldn't care less. Their only concern is price vs. efficacy vs. safety.

So come again: what do you think will be the price point for oral sema? Like Jardiance, like Ozempic, or "somewhere" in between? See, there is no really good answer from a Novo perspective. You lose one way or the other.

#inoveryourhead #getreal #emparules
 




anonymous said:
OK, Novo's very own Donald T, please share with us what the fake news is about. How about starting with the facts?
1. Empaglifozin (Jardiance) is the only treatment for T2D with an FDA approved label "to reduce the risk of cardiovascular death in adults with type 2 diabetes and established cardiovascular disease." Not even Ozempic could get that kind of label approved in the US!
2. Oral sema only narrowly beat Jardiance on HbA1c in the PIONEER 2 trial while there was no statistically significant difference in weight loss.
3. 11% of people treated with oral sema discontinued treatment due to nausea whereas only 4% dropped out in the Jardiance arm.
4. Ozempic and Trulicity are right now priced at least 35-40% higher than Jardiance.

Those were the facts. What is it we don't get here? That Novo is being carried away by the ability to put a protein into a tablet? Big deal. The patients - and importantly the payers - couldn't care less. Their only concern is price vs. efficacy vs. safety.

So come again: what do you think will be the price point for oral sema? Like Jardiance, like Ozempic, or "somewhere" in between? See, there is no really good answer from a Novo perspective. You lose one way or the other.

#inoveryourhead #getreal #emparules
Click to expand...

1. It will

2. This is either a bald faced lie or you’re just really misinformed. A 55% difference in 26 weeks and 62% different in 52 weeks. statistically significant difference in both and significant huge difference in Patient making goal.

Weight loss was insignificant at 26 weeks but was significant at 52

https://www.fiercepharma.com/pharma...s-jardiance-phase-3-but-some-questions-remain


You don’t know what you’re talking about. Go back to the Lilly board.
 




anonymous said:
OK, Novo's very own Donald T, please share with us what the fake news is about. How about starting with the facts?
1. Empaglifozin (Jardiance) is the only treatment for T2D with an FDA approved label "to reduce the risk of cardiovascular death in adults with type 2 diabetes and established cardiovascular disease." Not even Ozempic could get that kind of label approved in the US!
2. Oral sema only narrowly beat Jardiance on HbA1c in the PIONEER 2 trial while there was no statistically significant difference in weight loss.
3. 11% of people treated with oral sema discontinued treatment due to nausea whereas only 4% dropped out in the Jardiance arm.
4. Ozempic and Trulicity are right now priced at least 35-40% higher than Jardiance.

Those were the facts. What is it we don't get here? That Novo is being carried away by the ability to put a protein into a tablet? Big deal. The patients - and importantly the payers - couldn't care less. Their only concern is price vs. efficacy vs. safety.

So come again: what do you think will be the price point for oral sema? Like Jardiance, like Ozempic, or "somewhere" in between? See, there is no really good answer from a Novo perspective. You lose one way or the other.

#inoveryourhead #getreal #emparules
Click to expand...


And one quick google search proves you wrong, idiot.

https://www.fiercepharma.com/pharma...s-jardiance-phase-3-but-some-questions-remain
 




anonymous said:
OK, Novo's very own Donald T, please share with us what the fake news is about. How about starting with the facts?
1. Empaglifozin (Jardiance) is the only treatment for T2D with an FDA approved label "to reduce the risk of cardiovascular death in adults with type 2 diabetes and established cardiovascular disease." Not even Ozempic could get that kind of label approved in the US!
...
Click to expand...

I think you have been watching your misleading DTC commercial which states that it is the only diabetes pill which has that indication, which is true. Victoza as you well know also has the CV indication for the reduction of MACE (cardiovascular death, non-fatal myocardial infarction, or non-fatal stroke).

Jardiance has the reduction in CV-related death, but not for MI or stroke, in its PI.

If you work for Lilly you are brainwashed and misguided beyond belief.
 




Former Lilly Rep, now Novo Rep.
So along the lines of being misinformed & brainwashed at Lilly is 100% spot on!
The Lilly trolls will be able to read the above sentence and know immediately that I am what I say I am by the choice of words I used. Novo Reps will not see it, but yes my former colleagues, you see it and know it.
My advice to you all back at Lilly is to remember who you are working for.
Yep, Dave Ricks. He absolutely despises sales and will take every dollar your division can generate and funnel it into the new Migrane drug that your fearless leader is now going to give away for free until Lilly can bribe offices into using it instead of Amgen’s. Any minor advantage will be blown into some huge deal where you will have to get on a CC and fake roll play bull in the ring over every little detail that no customer would every stick around long enough to listen to. Also, you know the way Lilly screws up every FDA process, it will take twice along as what they tell you over there. Also, good luck making any $. Ops will just jack up the quotas and make the metrics on product weighting work against you.
 








Top Bottom
Back
Quote